EasySep™小鼠TIL(CD45)正选试剂盒

小鼠CD45+ TILs免疫磁珠正选

产品号 #100-0350

从实体瘤单细胞悬液中通过免疫磁珠正选小鼠CD45+ TILs

产品优势

  • 操作简单、快捷,且无需分离柱
  • 针对肿瘤和CD45起始占比低的组织样本进行了优化
  • 实验方法可灵活调整以实现更高的纯度或回收率

产品组分包括

  • EasySep™ 小鼠TIL(CD45)正选抗体混合物组分A,0.25 mL
  • EasySep™ 小鼠TIL(CD45)正选抗体混合物组分B,0.25 mL
  • EasySep™ 小鼠TIL(CD45)正选抗体混合物组分C,1.5 mL
  • EasySep™ Dextran RapidSpheres™ 50100 磁珠,2 x 1 mL

概述

使用EasySep™小鼠TIL(CD45)正选试剂盒,通过免疫磁珠正选轻松分离高纯度的小鼠CD45+肿瘤浸润白细胞(TILs)。该试剂盒已针对小鼠实体瘤的单细胞悬液进行了优化,包括将4T1、B16-F10和CT26.WT细胞系植入同品系小鼠来诱导的肿瘤。由于不同小鼠肿瘤的异质性,该试剂盒可能需要优化。EasySep™技术结合单克隆抗体的特异性和无柱磁分选系统的简便性,已在发
表的研究中广泛应用超过20年。

在此EasySep™正选流程中,目标细胞通过识别CD45的抗体复合物和磁珠进行标记,并通过EasySep™磁极分选。最后只需简单倾倒或弃去非目的细胞,目的细胞则保留在试管中。磁珠分选后,所需的CD45+ TILs 可立即用于下游应用,例如流式细胞术、培养和基于细胞的实验。
了解更多关于免疫磁珠EasySep™技术的工作原理。探索更多为您实验流程优化的其它产品,包括培养基、补充剂、抗体等。

MAGNET COMPATIBILITY
• EasySep™ Magnet (Catalog #18000)
• “The Big Easy” EasySep™ Magnet (Catalog #18001)
• EasyEights™ EasySep™ Magnet (Catalog #18103)
 
SUBTYPE
Cell Isolation Kits
 
CELL TYPE
Leukocytes
 
SPECIES
Mouse
 
SAMPLE SOURCE
Other, Tumor
 
SELECTION METHOD
Positive
 
APPLICATION
Cell Isolation
 
BRAND
EasySep
 
AREA OF INTEREST
Cancer, Immunology

实验数据

FACS plot showing cell populations from lung tissue pre- and post-cell isolation using the EasySep™ Mouse F4/80 Positive Selection Kit

Figure 1. Typical EasySep™ Mouse F4/80 Positive Cell Isolation Profile from Lung Tissue

Starting with a naïve mouse lung single-cell suspension, the F4/80+ cell content of the isolated fraction is typically 94.3 ± 2.8% (mean ± SD) using the purple EasySep™ magnet. In the above example, the purities of the start and final isolated fractions are 26.3% and 95.3%, respectively.

Typical Profile for F4/80+ Cells Isolated from Peritoneal Lavage Using the EasySep™ Mouse F4/80 Positive Selection Kit

Figure 2. Typical EasySep™ Mouse F4/80 Positive Cell Isolation Profile from Peritoneal Lavage

Starting with lavage cells from the peritoneal cavity of a naïve mouse, the F4/80+ cell content of the isolated fraction is typically 97.0 ± 0.4% (mean ± SD) using the purple EasySep™ magnet. In the above example, the purities of the start and final isolated fractions are 47.9% and 97.0%, respectively.

FACS plot showing cell populations from spleen pre- and post-cell isolation using the EasySep™ Mouse F4/80 Positive Selection Kit

Figure 3. Typical EasySep™ Mouse F4/80 Positive Cell Isolation Profile from Spleen

Starting with naïve mouse splenocytes, the F4/80+ cell content of the isolated fraction is typically 88.8 ± 3.4% (mean ± SD) using the purple EasySep™ magnet. In the above example, the purities of the start and final isolated fractions are 5.4% and 90.6%, respectively.

产品说明书及文档

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
100-0659
Lot #
1000158053 or lower
Language
English
Catalog #
100-0659
Lot #
1000158054 or higher
Language
English
Catalog #
100-0659
Lot #
1000158053 or lower
Language
English
Catalog #
100-0659
Lot #
1000158054 or higher
Language
English
Catalog #
100-0659
Lot #
1000158053 or lower
Language
English
Catalog #
100-0659
Lot #
1000158054 or higher
Language
English
Document Type
Safety Data Sheet 1
Catalog #
100-0659
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
100-0659
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0659
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
100-0659
Lot #
All
Language
English
Document Type
Safety Data Sheet 5
Catalog #
100-0659
Lot #
All
Language
English

应用领域

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

相关材料与文献

Educational Materials (7)

Publications (1)

Novel lipid emulsion for total parenteral nutrition based on 18-carbon n-3 fatty acids elicits a superior immunometabolic phenotype in a murine model compared with standard lipid emulsions. E. Lucchinetti et al. The American journal of clinical nutrition 2022 dec

Abstract

BACKGROUND While lipid emulsions in modern formulations for total parenteral nutrition (TPN) provide essential fatty acids and dense calories, they also promote inflammation and immunometabolic disruptions. OBJECTIVES We aimed to develop a novel lipid emulsion for TPN use with superior immunometabolic actions compared with available standard lipid emulsions. METHODS A novel lipid emulsion [Vegaven (VV)] containing 30% of 18-carbon n-3 fatty acids ($\alpha$-linolenic acid and stearidonic acid) was developed for TPN (VV-TPN) and compared with TPN containing soybean oil-based lipid emulsion (IL-TPN) and fish-oil-based lipid emulsion (OV-TPN). In vivo studies were performed in instrumented male C57BL/6 mice subjected to 7-d TPN prior to analysis of cytokines, indices of whole-body and hepatic glucose metabolism, immune cells, lipid mediators, and mucosal bowel microbiome. RESULTS IL-6 to IL-10 ratios were significantly lower in liver and skeletal muscle of VV-TPN mice when compared with IL-TPN or OV-TPN mice. VV-TPN and OV-TPN each increased hepatic insulin receptor abundance and resulted in similar HOMA-IR values, whereas only VV-TPN increased hepatic insulin receptor substrate 2 and maintained normal hepatic glycogen content, effects that were IL-10-dependent and mediated by glucokinase activation. The percentages of IFN-$\gamma$- and IL-17-expressing CD4+ T cells were increased in livers of VV-TPN mice, and liver macrophages exhibited primed phenotypes when compared with IL-TPN. This immunomodulation was associated with successful elimination of the microinvasive bacterium Akkermansia muciniphila from the bowel mucosa by VV-TPN as opposed to standard lipid emulsions. Assay of hepatic lipid mediators revealed a distinct profile with VV-TPN, including increases in 9(S)-hydroxy-octadecatrienoic acid. When co-administered with IL-TPN, hydroxy-octadecatrienoic acids mimicked the VV-TPN immunometabolic phenotype. CONCLUSIONS We here report the unique anti-inflammatory, insulin-sensitizing, and immunity-enhancing properties of a newly developed lipid emulsion designed for TPN use based on 18-carbon n-3 fatty acids.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。